| アブストラクト | BACKGROUND: Nivolumab combined with ipilimumab (NIVO-IPI) and nivolumab combined with relatlimab (NIVO-RELA) are approved treatments for advanced melanoma. However, the data on the differential adverse event (AE) risks associated with these two regimens are lacking. METHODS: We performed a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database for NIVO-IPI and NIVO-RELA from the fourth quarter (Q4) of 2015 to Q4 of 2024. We calculated the reporting odds ratios (ROR) and information component (IC) with 95% confidence intervals (CIs). RESULTS: A total of 7,482 records for NIVO-IPI and 185 records for NIVO-RELA were extracted from FAERS. NIVO-IPI showed significantly higher risks for gastrointestinal (ROR = 1.39), endocrine (ROR = 3.10), hepatobiliary (ROR = 2.32), metabolism and nutrition (ROR = 1.44), and respiratory, thoracic, and mediastinal disorders (ROR = 1.18), particularly in preferred terms (PTs) such as colitis, hypophysitis, pneumonia, and hepatitis. NIVO-RELA was associated with increased risks for cardiac (ROR = 2.84) and vascular disorders (ROR = 2.04), notably in PTs like myocarditis, troponin elevation, and myasthenia gravis. 80% of AEs occurred within three months for both regimens. The median time-to-onset was 42 days for NIVO-IPI compared to 57 days for NIVO-RELA, with no statistically significant difference (p = 0.66). CONCLUSION: NIVO-IPI is linked with a broader range of immune-related toxicities, whereas NIVO-RELA presents higher cardiac-specific risks. These findings emphasize the need for tailored AE monitoring based on treatment selection. |
|---|
| ジャーナル名 | BMC cancer |
|---|
| Pubmed追加日 | 2025/7/20 |
|---|
| 投稿者 | Xu, Shanshan; Song, Zhihui; Wang, Dong; Wang, Ente; Wang, Jiawei |
|---|
| 組織名 | Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University,;No.1 Dongjiaomin Lane, Dongcheng District, Beijing, China.;No.1 Dongjiaomin Lane, Dongcheng District, Beijing, China. wangjw2023@126.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40684089/ |
|---|
